Tim Mayleben

August 10, 2020

Tim M. Mayleben was appointed Lead Independent Director in November 2022 and has served on our Board since December 2008.

Mr. Mayleben has more than two decades of executive leadership experience in the life sciences industry, most recently as President, CEO and Director of Esperion Therapeutics, Inc, a pharmaceutical company developing and commercializing non-statin, oral medicines for patients with elevated levels of LDL-cholesterol, where he led the development and approval of Nexletol and Nexlizet, the first such medicines approved in almost 20 years. Prior to Esperion, he was President, CEO and Director of Vericel Corporation, (previously named Aastrom Biosciences), former President, COO, and a director of Virtual Radiologics, Inc. (formerly NightHawk Radiology Holdings, Inc.), and former COO and CFO of the original Esperion, until its acquisition by Pfizer in 2004.

Mr. Mayleben earned an MBA, with distinction, from the J.L. Kellogg Graduate School of Management at Northwestern University, and a BBA from the University of Michigan, Ross School of Business.